CoImmune

Recent Finacing

Series A

Recent Raise

$45M

CoImmune develops immuno-oncology therapies using an autologous RNA-loaded dendritic cell platform for solid tumors and an allogeneic CAR-CIK platform for hematologic cancers, advancing CMN‑001 in RCC clinical trials.

Founded 2019

North Carolina, United States

11-50

Private

coimmune.com

Highlights

Focus Areas

Biotechnology

Therapeutics

Financials

$45M

Total Raised

1

Funding round

Team

Upgrade to view the team

See the team members at CoImmune.